Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies to enter clinic H2 2026 - - Advancing Voyager NeuroShuttle™: murine study using anti-amyloid

#VYGR Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

www.stocktitan.net/news/VYGR/voyager-report...

Voyager Reports Third Quarter 2025 Financial and Operating Results - Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining

#VYGR Voyager Reports Third Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/VYGR/voyager-report...

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to

#VYGR Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

www.stocktitan.net/news/VYGR/transition-bio...

Trade Alert, Wednesday November 5, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend, Av Dir Indx, Wed Nov 5th - #SNDL #PNRG #NNOX #MCRB #LCUT #KRNT #HEPS #CPIX #DEFT #ELTX #GSM #VYGR #BAND #ABEO #BBAI #SI #PRG #ONTF #MVO #MNTN #HPP #FPI #CABO #TIL - More: crystalequityresearch.com/trade-alert-... - #smallcap

Voyager Therapeutics Secures Future Through 2028 with $262M Cash, Expands Alzheimer's Pipeline to 4 Programs Biotech firm strengthens financial position with extended runway, advances multiple clinical programs including new APOE Alzheimer's asset. See milestone potential.

#VYGR Voyager Reports Second Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/VYGR/voyager-report...

Leading Indicators, Wednesday July 30, 2025 – Crystal Equity Research

Small-cap stocks in new uptrend with AROON Oscillator, Wed Jul 30th - #XTKG #VYGR #SENEA #RCKY #NWPX #LAB #FAT #EWTX #BRY #ATXS #TNK #NAT #LXFR #GCI #BRSP #ASC - More: crystalequityresearch.com/leading-indi... - #smallcap

Breakthrough: Voyager Unveils Fourth Alzheimer's Program Targeting APOE Gene, Major Risk Factor New gene therapy program targets APOE4 risk variant while delivering protective APOE2 variant. Expands Voyager's Alzheimer's portfolio to four programs. See breakthrough details.

#VYGR Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

www.stocktitan.net/news/VYGR/voyager-adds-f...

Revolutionary Brain Drug Delivery: Voyager's New Gene Therapy Shows 400x Improvement in Landmark Research Just published: Groundbreaking ALPL receptor technology enables 400x better brain drug delivery. Novel AAV capsid reaches 98% of target neurons. See the breakthrough data.

#VYGR Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

www.stocktitan.net/news/VYGR/voyager-demons...

Voyager's Alzheimer's Breakthrough: New Gene Therapy Shows 73% Tau Reduction, Runway Extended to 2027 Latest data reveals promising 73% tau knockdown in Alzheimer's treatment. Strong $295M cash position extends runway to 2027. See complete pipeline updates.

#VYGR Voyager Reports First Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/VYGR/voyager-report...

New Alzheimer's Breakthrough: Single-Dose Gene Therapy Slashes Tau Levels by 73% Novel gene therapy achieves sustained tau reduction with single IV dose. Breakthrough shows potential for transformative Alzheimer's treatment. Full efficacy data inside.

#VYGR Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

www.stocktitan.net/news/VYGR/voyager-presen...

Pomerantz Law Firm Launches Investigation into Voyager Therapeutics Investor Claims Pomerantz LLP is probing claims from Voyager Therapeutics investors concerning potential securities fraud and legal misconduct by company executives.

Pomerantz Law Firm Launches Investigation into Voyager Therapeutics Investor Claims #United_States #New_York #Pomerantz_LLP #Voyager_Therapeutics #VYGR

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results Voyager Therapeutics (VYGR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its tau-targeting programs for Alzheimer's disease. The company's tau silencing gene therapy VY1706 showed promising results in NHP studies, with 50-73% reduction in tau mRNA levels across the cerebral cortex. Their anti-tau antibody VY7523 demonstrated positive safety and pharmacokinetic results in Phase 1 trials.Financial highlights include: Q4 2024 collaboration revenue of $6.3M vs $90.1M in Q4 2023Full year 2024 revenue of $80M vs $250M in 2023Q4 2024 net loss of $34.5M vs net income of $56.4M in Q4 2023Cash position of $332.4M as of December 31, 2024The company expects cash runway into mid-2027 and anticipates several key milestones, including IND filings for GBA1 Parkinson's therapies in 2025 and tau PET imaging data from VY7523 trials in H2 2026.

#VYGR Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

www.stocktitan.net/news/VYGR/voyager-report...

Pomerantz Law Firm Investigates Voyager Therapeutics for Potential Securities Fraud Among Investors Pomerantz LLP is probing potential securities fraud involving Voyager Therapeutics, sparking concerns among investors following the company's recent announcements.

Pomerantz Law Firm Investigates Voyager Therapeutics for Potential Securities Fraud Among Investors #無し #Pomerantz_LLP #Voyager_Therapeutics #VYGR

Schall Law Firm Investigates Voyager Therapeutics Fraud Allegations: A Vital Opportunity for VYGR Investors The Schall Law Firm is investigating potential fraud claims against Voyager Therapeutics, providing investors an opportunity to join the investigation following significant stock declines.

Schall Law Firm Investigates Voyager Therapeutics Fraud Allegations: A Vital Opportunity for VYGR Investors #United_States #Los_Angeles #Schall_Law_Firm #Voyager_Therapeutics #VYGR

Voyager's ALS Program Hits Critical Safety Hurdle, Pipeline Strategy Shifts Voyager Therapeutics suspends VY9323 ALS therapy due to off-target effects in primate studies, extends cash runway to 2027 while other programs remain on track.

#VYGR Voyager Provides Update on SOD1 ALS Gene Therapy Program

www.stocktitan.net/news/VYGR/voyager-provid...

#VYGR Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

www.stocktitan.net/news/VYGR/voyager-select...

• 6 AU CHALLENGE •
Req Oc AU !!

🖼️ template : drive.google.com/drive/folder...

#OCsky #OC #SnM_Ocs #artrequest #SPNV #VYGR

“ ᴇɪɴ ᴋʟᴇɪɴᴇʀ ꜱᴄʜʀɪᴛᴛ ”
❶❾❻❾

My Oc project .𖥔 ݁ ˖ 🌘

#oc #VYGR #OCsky #magma #doodles #rkgk

Just In: ( NASDAQ: #VYGR ) Learn to Evaluate (VYGR) using the Charts

#StockMarket #News